IntelliPharmaCeutics International Inc News - IPCI | Aktien Toronto Börse

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Intellipharmaceutics Provides Operational Update

TORONTO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Announces Receipt of Nasdaq Notice

TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) and...

Intellipharmaceutics Announces Closing of US$4 Million Financing

TORONTO, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Announces US$4 Million Registered Direct Offering

TORONTO, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Announces Third Quarter 2017 Results

TORONTO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI...

Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA

TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Announces Receipt of Nasdaq Notice

TORONTO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Provides Operational Update

TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Appoints New Chief Financial Officer

TORONTO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Announces Resignation of Chief Financial Officer

TORONTO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit

TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended rele...

TORONTO, July 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Intellipharmaceutics Announces Second Quarter 2017 Results

TORONTO, July 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI...

Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an A...

TORONTO, June 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI...

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

IntelliPharmaCeutics International Inc (IPCI)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

IPCI Nachrichten

Intellipharmaceutics Provides Operational Update

Intellipharmaceutics Announces Receipt of Nasdaq Notice

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

Intellipharmaceutics Announces Closing of US$4 Million Financing

Intellipharmaceutics Announces US$4 Million Registered Direct Offering

Intellipharmaceutics Announces Third Quarter 2017 Results

Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA

Intellipharmaceutics Announces Receipt of Nasdaq Notice

Intellipharmaceutics Provides Operational Update

Intellipharmaceutics Appoints New Chief Financial Officer

Intellipharmaceutics Announces Resignation of Chief Financial Officer

Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended rele...

Intellipharmaceutics Announces Second Quarter 2017 Results

Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an A...

IPCI Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

IntelliPharmaCeutics International Inc (IPCI) News

IntelliPharmaCeutics International Inc (IPCI)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

IPCI Nachrichten

Intellipharmaceutics Provides Operational Update

Intellipharmaceutics Announces Receipt of Nasdaq Notice

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

Intellipharmaceutics Announces Closing of US$4 Million Financing

Intellipharmaceutics Announces US$4 Million Registered Direct Offering

Intellipharmaceutics Announces Third Quarter 2017 Results

Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA

Intellipharmaceutics Announces Receipt of Nasdaq Notice

Intellipharmaceutics Provides Operational Update

Intellipharmaceutics Appoints New Chief Financial Officer

Intellipharmaceutics Announces Resignation of Chief Financial Officer

Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended rele...

Intellipharmaceutics Announces Second Quarter 2017 Results

Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an A...

IPCI Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen